Pharma Growth Story: Jubilant Pharmova's Shareholder Value

$JUBLPHARMA Jubilant Pharmova is a global vertically integrated pharmaceutical company operating across pharmaceuticals, contract research, development services, and proprietary novel drugs. It has the second-largest commercial radiopharmacy network in the US and ranks second globally in allergenic extracts. FY25 performance showed strong momentum. Revenue grew 8% YoY to Rs 7,235 crore. EBITDA rose 24% to Rs 1,230 crore with margin expansion of 220 bps. PAT surged 1,050% to Rs 836 crore, while normalized PAT increased 112% to Rs 415 crore. Segment-wise performance remained diversified and robust. Radiopharmaceuticals revenue increased 13% to Rs 1,074 crore, while Radiopharmacy grew 13% to Rs 2,314 crore. Allergy Immunotherapy revenue reached Rs 701 crore with healthy EBITDA margins of 35%. CDMO Sterile Injectables revenue rose 14% to Rs 1,272 crore and EBITDA jumped 52% to Rs 292 crore. CRDMO revenue expanded 27% to Rs 570 crore, and API revenue stood at Rs 581 crore with EBITDA growth of 39%. Management’s Vision 2030 targets doubling revenue between FY24–FY30, achieving EBITDA margins of 23–25%, maintaining zero net debt, and delivering return on capital in the high teens. Net debt has already reduced materially, supported by prepayment of Rs 626 crore term debt at its US subsidiary. Current market capitalization is Rs 17,350 crore. For shareholders, diversified revenue streams reduce concentration risk, margin expansion reflects improving operating efficiency, and debt reduction strengthens financial resilience. Growth in CDMO and specialty businesses aligns with long-term global healthcare outsourcing trends. Key concerns remain: ROCE and ROE at ~9.5% indicate moderate capital efficiency, valuation is elevated at 34.9x earnings, five-year sales CAGR is only 3.9%, and promoter holding declined to 47.7%. Overall, Jubilant Pharmova presents a strong long-term opportunity supported by improving fundamentals, specialty positioning, and execution momentum.